- Gene and cell therapy group Oxford BioMedica said it had formed a new digital framework initiative to streamline production of next-generation medicines.

The company said it would invest £4m in the initiative, supported by a £2m grant from the UK government.

It would involve building digital and robotics capabilities designed to drive improvements in analytical methodology, supply times and cost of goods.

The goal was to increase capacity, reduce the cost of manufacturing and reduce waste.

'With demand for advanced therapy medicinal products expected to grow at unprecedented levels, underlined by the interest received from our current and future potential partners, it is imperative that we continue to invest in our technology, capacity and innovation,' chief executive John Dawson said.

'This new initiative will provide us with digital and robotic enhancements to maintain our global leading position in the development and manufacture of lentiviral vector products.'

'This is important for our own R&D pipeline as well as for our blue-chip partners as we continue to support the delivery of life-altering gene therapies to patients around the world.'

Story provided by